NCT02941042

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects being Overweight or with Obesity

Conditions

• Metabolism and Nutrition Disorder
• Obesity

Interventions

Type	Name	Description
DRUG	NNC9204-1177	A single dose administered subcutaneously ( s.c. under the skin)
DRUG	Placebo	A single dose administered subcutaneously ( s.c. under the skin)

Timeline

• Start date: 2016-10-10
• Primary completion: 2017-09-30
• Completion: 2017-09-30
• First posted: 2016-10-21
• Last updated: 2018-09-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study